Renal Renaissance: Empowering CKD Management with SGLT2 Inhibitors

Authors

Charlie Wright Pharm.D., Harding UniversityFollow
Austin Moore, Harding UniversityFollow

Document Type

Article

Publication Title

ACCP Adult Medicine PRN Newsletter

Publication Date

Spring 5-2024

First Page

10

Last Page

12

Abstract

CKD is often a silent disease in its early stages and many individuals do not experience symptoms until their kidney function is significantly impaired. Risk factors include type 2 diabetes mellitus (T2DM), hypertension, a family history of kidney failure, and age over 60. Until recently, pharmacotherapy options for managing CKD have been relatively limited with options including the use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in conjunction with lifestyle modifications. Sodium- Glucose Co-Transporter 2 (SGLT2) inhibitors have emerged as a promising therapeutic option. These drugs demonstrate renoprotective effects by slowing the progression of CKD. In addition, these drugs are utilized in T2DM and select agents in the class demonstrate clinical benefit in the setting of heart failure and in reducing cardiovascular events.(2) Thus, the integration of SGLT2 inhibitors into pharmacy practice offers a novel approach to managing CKD and its comorbidities.

Copyright held by

American College of Clinical Pharmacy

Recommended Citation

Wright, C. (2024). Renal renaissance: Empowering CKD management with SGLT2 inhibitors. ACCP Adult Medicine PRN Newsletter, Spring 2024, 10-12, 21.